Lymphoid Neoplasia

Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphoid neoplasia.

Patient Dies After Developing Resistance to CAR T-Cell Therapy

A young patient with B-cell acute lymphocytic leukemia who received chimeric antigen receptor (CAR) T-cell therapy developed a resistance to his treatment, according to...

FDA Approves Duvelisib for Patients with CLL or SLL

The U.S. Food and Drug Administration has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia...

FDA Approves NGS-Based Test for Patients With ALL or MM

The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal residual disease (MRD) in...

European Commission Expands Blinatumomab’s Approval for ALL

The European Commission (EC) has approved an expanded indication for blinatumomab to include the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-negative) relapsed or...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Is Chronic Lymphocytic Leukemia Curable With Newer Agents?

Chronic lymphocytic leukemia (CLL) has long been considered an incurable disease. The goal of traditional frontline treatments is to minimize disease burden and allow...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

Extended Analysis Shows Venetoclax Continues to Produce Deep Responses in CLL

In 2016, the U.S. Food and Drug Administration granted venetoclax accelerated approval for the treatment of adults with previously treated chronic lymphocytic leukemia (CLL)...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...
Advertisement

Current Issue

October 2018, Volume 4, Issue 12

This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.